



**Curriculum vitae  
Europass**

**Informații personale**

Nume / Prenume

**GALEȘ LAURENȚIA NICOLETA**

Locul de muncă vizat /  
Domeniul ocupațional

UMF Carol Davila București  
Institutul Oncologic Prof Dr Al Trestioreanu București  
Medicină

**Experiența profesională**

Perioada

**Feb 2024 – prezent – Medic Șef Secție Oncologie Medicală II**  
**Oct 2021 – feb 2024 – Director Medical - Institutul Oncologic Prof Dr Al Trestioreanu București**  
**2016 – prezent – Conferențiar universitar - UMF Carol Davila București**  
2015 – Doctor în medicină  
2015 – Medic specialist radioterapie  
2009 – 2016 – Șef lucrări - UMF Carol Davila București  
2003-2009 – Asistent universitar - UMF Carol Davila București  
**2008-prezent - Medic primar oncologie medicală - Institutul Oncologic Prof Dr Al Trestioreanu București**  
2003-2008 - Medic specialist oncologie medicală – Institutul Oncologic Prof Dr Al Trestioreanu București  
2002-2003 - Oncolog medical – Ambulatoriul Sp. Cl. Sf. Ioan București  
1997-2002 - Rezident oncologie medicală - Institutul Oncologic Prof Dr Al Trestioreanu București

Funcția sau postul  
ocupat

**Conferențiar - UMF Carol Davila București**  
**Medic primar oncologie medicală - Institutul Oncologic Prof Dr Al Trestioreanu București – Director medical**

Activități și  
responsabilități principale

Activitate medicală – diagnostic și tratament pacienți oncologici  
Activitate didactică – predare și îndrumare studenți și rezidenți oncologie  
Activitate de cercetare – studii clinice

Numele și adresa angajatorului UMF Carol Davila București – Bulevardul Eroii Sanitari Nr. 8. Sector 5 București  
Institutul Oncologic Prof Dr Al Trestioreanu București – Șoseaua Fundeni Nr 252 Sector 2 București

Tipul activității sau sectorul de activitate Medicină

### Educație și formare

Perioada 2015  
Calificarea / diploma Titlul de Doctor în Medicină  
obținută Domeniul Oncologie  
Disciplinele principale studiate / competențe profesionale dobândite UMF Carol Davila București – Școala Doctorală  
Numele și tipul instituției de învățământ / furnizorului de formare

Perioada 2015  
Calificarea / diploma Medic specialist radioterapie 1152/mar 2015  
obținută  
Disciplinele principale studiate / competențe profesionale dobândite Radioterapie  
Numele și tipul instituției de învățământ / furnizorului de formare Institutul Oncologic Prof Dr Al Trestioreanu București

Perioada 2008  
Calificarea / diploma Medic primar oncologie medicală 398/15/12.2008  
obținută B06-1012/4  
Disciplinele principale studiate / competențe profesionale dobândite Oncologie medicală  
Numele și tipul instituției de învățământ / furnizorului de formare Institutul Oncologic Prof Dr Al Trestioreanu București

Perioada 1997-2002  
Calificarea / diploma Medic specialist oncologie medicală 256/03.2002  
obținută  
Disciplinele principale studiate / competențe profesionale dobândite Oncologie medicală  
Numele și tipul instituției de învățământ / furnizorului de formare Institutul Oncologic Prof Dr Al Trestioreanu București

Perioada 1990 - 1995  
Calificarea / diploma Doctor medic  
obținută

Disciplinele principale studiate / competențe profesionale dobândite Medicină generală N023109

Numele și tipul instituției de învățământ / furnizorului de formare Universitatea Ovidius Constanța

Nivelul în clasificarea națională sau internațională

Aptitudini și competențe personale

Limba(i) maternă(e) română

Limba(i) străină(e) cunoscută(e)

Autoevaluare

Nivel european (\*)

Engleza

Limba

Înțelegere		Vorbire		Scriere
Ascultare	Citire	Participare la conversație	Discurs oral	Exprimare scrisă
C1	B2	C1	B2	B2

(\*) Nivelul Cadrului European Comun de Referință Pentru Limbi Străine

Competențe și abilități sociale

Competențe și aptitudini organizatorice Școala Națională de Studii Politice și Administrative – Studii Academice Postuniversitare – științe administrative – 2003-2006

Ministerul Sănătății – Școala Națională de Sănătate Publică, Management și Perfecționare în Domeniul Sanitar București – Atestat în Managementul Serviciilor de Sănătate – 27.09.2021 – 09.03.2022

Competențe și aptitudini tehnice

Competențe și aptitudini de utilizare a calculatorului Utilizare windows, office (word, power point, excell, etc.)

Competențe și aptitudini artistice

Alte competențe și aptitudini - Centrul Național de Perfecționare Postuniversitară a Medicilor, Farmaciștilor, Alții Personal cu Studii Superioare și Asistenților Medicali - Curs de pregătire pentru dobândirea competenței în Îngrijiri paliative – 2003 – 2005

Permis(e) de conducere

Permis categoria B

Informații suplimentare

**Membră Societăți profesionale naționale și internaționale:**

ESMO (European Society of Medical Oncology) din 2000

ASCO (American Society of Clinical Oncology) din 2001

SIOG (International Society of Geriatric Oncology), din 2018, National representative – 2018-2019, 2024

RSM (The Royal Society of Medicine) din Marea Britanie

SNOMR (Societatea Națională de Oncologie Medicală din România) – Membru în Comitetul Director din 2023

SRR (Societatea Română de Radioterapie)

SRROM (Societatea Română de Radioterapie și Oncologie Medicală)

Colegiul Medicilor din România

Colegiul Medicilor din Municipiul București

**Teza de Doctorat**

Studiul, cercetarea și aplicarea în clinica oncologică a tratamentului prin captarea neutronilor de către B-10

**Lista lucrărilor științifice** Gales, Laurentia - Web of Science Core Collection, <https://orcid.org/0000-0002-0414-1607> - **Anexa 1**

**Cărți și capitole din cărți: autor/ coautor capitole – 10 carti**

**Articole/studii in extenso publicate în reviste cotate ISI, indexate PubMed sau alte BDI, CNCSIS: - 76**  
Web of Science Core Collection publications

**Publicații in extenso, apărute în lucrări ale principalelor conferințe internaționale de specialitate și rezumate ale lucrărilor prezentate la conferințe internaționale de specialitate, publicate în reviste cotate ISI: 116**

**Alte lucrări și contribuții științifice: - 184 lucrări prezentate la conferințe naționale sau regionale**

**Cercetare: 4 proiecte de cercetare cu finanțare națională**

1. BNCT. Studiul, cercetarea și abordarea în clinica oncologică a radioterapiei cu neutroni captati de catre Bor-10 – PC-D01-PT11-94 (2005) **membru în echipa de proiect**
2. TARD. Dezvoltarea și testarea unui sistem automat de analiza a riscului, diagnoza și decizie pentru asistarea actului medical – PC-D03-PT03-1244 (2005) **membru în echipa de proiect**
3. Proiect VIASAN 435 – “Testarea genetică la femeile cu risc de neoplasm mamar ereditar” – Proiect al fundației Dr V Babes cu Partener Institutul Oncologic A Trestioreanu Bucuresti – **responsabil de proiect partener**
4. PNRR-III-C9-2022 – 15 - Crearea, Operaționalizarea și Dezvoltarea Centrului Național de Competență în domeniul cancerului – **responsabil WP2 (WP leader) CD2 UMFC**

**Responsabil de proiect pentru proiectele EU4H INTERACT EUROPE și INTERACT EUROPE 100 din partea partenerului UMFC**

**Membru în echipa de proiect pentru proiectele EU4H SOLACE și TRANSITION**

**Studii clinice: 86 studii clinice internaționale ca subinvestigator sau investigator principal – Anexa 2**

14.06.2024

## GALEȘ LAURENȚIA NICOLETA

### ANEXA 2 - LISTA STUDIIL CLINICE

#### Ca SubInvestigator:

1. H3E-MC-JMEN Maintenance Therapy Studiu de faza 3, dublu-orb, controlat placebo, al pemetrexed de intretinere plus cea mai buna asistenta suportiva versus cea mai buna asistenta suportiva imediat dupa tratamentul de inducere pentru cancer pulmonar avansat fara celule mici
2. CECOG/ GIST 1.2.001 Studiu clinic deschis utilizand Glivec la pacienti cu tumori gastrointestinale neoperabile sau metastatice maligne cu c-kit exprimat
3. H3E-MC-JMDV Studiu clinic de faza 1/2 privind cresterea dozei de Alimta si Cyclophosphamida administrate la fiecare 21 de zile la pacientele cu cancer de san local avansat sau metastatic
4. 3066A1-303-WW Studiu de faza 3 randomizat, controlat placebo, dublu-orb al administrarii orale a CCI-779 in combinatie cu Letrozole versus Letrozole singur ca terapie hormonala de prima linie la femeile postmenopauza cu cancer de san local avansat sau metastatic
5. CECOG/CORE 1.2.001 Studiu de faza II, deschis, randomizat care evalueaza eficacitatea si siguranta folosirii tratamentului cu FOLFOX 6 + CETUXIMAB versus FOLFIRI + CETUXIMAB ca prima linie de tratament la pacientii cu cancer colorectal metastazat.
6. MO18024 Tratament de prima linie cu bevacizumab in combinatie cu chimioterapia in cancerul colorectal metastatic
7. A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer – H3E-MC-JMHO
8. EFC10547 – VANILLA - A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer
9. H3E-MC-JMHR A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
10. CECOG/CORE 1.2.002 A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + Weekly Cetuximab versus FOLFOX4 + biweekly Cetuximab as first line therapy in patients with k-ras wild-type metastatic colorectal cancer

11. KF5503/15 A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignant tumor-related pain
12. EMR 63325 A multi-center phase III randomized, double blind placebo-controlled study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease.
13. CECOG/BC.1.3.005: -"A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer"
14. BO21990 - A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma - AVAGLIO
15. A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting - PHEREX
16. CELLTRION CT-P6 - 3.1 / A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer
17. A randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition of Cp-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer - A4021017
18. EFC 11784 - Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m<sup>2</sup> and at 20 mg/m<sup>2</sup> in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
19. EFC11785 / randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m<sup>2</sup> and at 25 mg/ m<sup>2</sup> Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration resistant Prostate cancer Previously Treated With a Docetaxel-Containing Regimen.

20. Efficacy and Safety of long-Term (6 Months) Innohep® Treatment versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT
21. AMG 386 Protocol No. 20090508 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
22. An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy. – PCR3001
23. A Phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and dexamethasone for the prevention of nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
24. A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7,5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit.
25. A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer. – AMG2010007
26. BROCADE - A Randomised, Phase 2 Study of the Efficacy and Tolerability of Veliparib in combination with Temozolomide or Veliparib in combination with Carboplatin and Paclitaxel versus Placebo plus Carboplatin and Paclitaxel in Subjects with BRCA 1 or BRCA 2 Mutation and Metastatic Breast Cancer.
27. A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy
28. A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
29. MK-0517-031 AM4 - A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant

Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy

30. A double-blind placebo-controlled, randomized, multicentric, Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2 –positive metastatic gastroesophageal junction and gastric cancer JACOB, BO25114
31. A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
32. NBTXR-301 Multicenter randomized, open-label phase II/III study, to compare efficacy of NBTXR3 implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma (extremity and trunk wall)
33. eMonarchER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy - I3Y-MC-JPCW
34. LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET FusionPositive Non-Small Cell Lung Cancer - J2G-MC-JZJC
35. CheckMate 9LA - A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
36. CheckMate 907 - An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen
37. CheckMate 743 - A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
38. CheckMate 227 - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy



- Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
39. CheckMate 915 - A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
  40. CARMEN-LC03, EFC15858 - Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors
  41. ALTA-3 - A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
  42. ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
  43. DS8201-A-U305 (DESTINY-Breast05; NSABP B-60; GBG-103; SOLTI-2001; AGO-B-050) A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (TDM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy
  44. A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non- Small Cell Lung Cancer – CA209-77T
  45. A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy – CA209-67T
  46. A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer – CA209-7DX
  47. ANAM-17-21 A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of

**Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)**

48. Un studiu de faza III, deschis, randomizat pentru a evalua eficacitatea si siguranta terapiei adjuvante cu alectinib versus chimioterapia adjuvanta cu compusi de platina la pacienti cu cancer pulmonar fara celule mici cu status pozitiv pentru kinaza din limfomul anaplazic, in stadiul IB complet rezecat (tumori  $>$  4 cm) pana la stadiul IIIA. (BO40336\_ALINA)
49. A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C. (CodeBreaK 100)
50. A Phase 3 Study of Front-Line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/Metastatic NSCLC (CodeBreaK 202)
51. Phase 2 study of telisotuzumab vedotin (Teliso-V) monotherapy in patients with previously untreated *MET*-amplified locally advanced/metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) (LUMINOSITY M14-239)
52. Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)
53. A Phase 2 and Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma- R3767-ONC-2011
54. A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma - R3767-ONC-2055

**Ca Investigator principal**

55. BESTFACT – Bonefos Treatment for Advanced Cancer – Studiu non-interventional, observational, post-autorizare despre utilizarea Bonefos (disodium clodronate) administrat oral in tratamentul tumorilor maligne cu afectare osoasa, in conditiile practicii medicale curente.

56. Studiu clinic multicentric, deschis, de faza II, evaluand eficacitatea tratamentului cu Tarceva prescris ca monoterapie, in linia I, la pacientii cu tip de cancer NSCLC ce prezinta mutatii la nivelul receptorului EGFR – ML22606
57. CRAD001YIC04 An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane
58. MK3475-059 A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
59. GO29294 A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy [imvigor211]
60. CORAIL Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer
61. A Phase III, Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin® in Subjects with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
62. ARCHES – A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
63. GLOW - A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
64. NERO – Impact of the Adherence to Antiemetic Guidelines in Cancer Patients Undergoing Repeated Cycles of Either MEC or HEC Regimens in Eastern Europe
65. AB12008 - A prospective, multicenter, open label, centrally allocated, active-controlled, phase 2/3 study to evaluate the efficacy and safety of masitinibin combination with

- gemcitabine versus gemcitabine alone in advanced/metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
66. EPIK-B3, CBYL719H12301: - A Phase III, multicenter, randomized, doubleblind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nabpaclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation
  67. A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non-Small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti PD (L)1 Therapy and Platinum-Based Chemotherapy- D533BC00001
  68. A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-101)
  69. Amgen 20210081 - Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus Investigator's Choice Chemotherapy (FOLFOX or FOLFIRI) with or without Bevacizumab-awwb for Treatment-naïve Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation.
  70. Phase 3 randomized study of DS-1062A versus docetaxel in previously treated advanced or metastatic non-small-cell lung cancer without actionable genomic alterations (TROPION-LUNG01)
  71. A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
  72. A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Bladder Cancer in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205)
  73. A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors – INCB 86550-203
  74. A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)

75. CJDQ443B12301: A randomized, open label, phase III study evaluating JQ443 or docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer – KontRASt-02
76. A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy – BGB-290-303
77. A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting (AMG 20220083)
78. ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) Unicancer-Peace 6 UC-GTG-2006
79. Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy - (VIKTORIA-1)
80. A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies
81. E0660 ASTEX - A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients with Moderate and Severe Hepatic Impairment
82. E0661 ASTEX - A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients with Severe Renal Impairment and Cancer Patients with Normal Renal Function
83. E0678 ASTEX -An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
84. E0757 JIMMY MEL SANDOZ Biosimilar - A randomized, double-blind, parallel-group study to compare pharmacokinetics of GME751 (proposed pembrolizumab biosimilar)

and US-licensed and EU authorized Keytruda® in participants with stage II and III melanoma requiring adjuvant treatment with pembrolizumab.

85. E0685 Beigene - A Phase 2, Open-label, Multi-Arm Study of Tieslizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, Or Metastatic Non-Small Cell Lung Cancer

86. E0594 - An open label trial of BI 765063 in combination with BI 754091 (ezabenzimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) (phase 1b)



14 06 2025